Retatrutide is a relatively large molecule, and aggressive reconstitution can denature portions of it, reducing potency
This is the dose used in many of the pivotal semaglutide studies, and it produces meaningful metabolic changes beyond simple appetite suppression
However, current evidence largely relies on animal models
While some experimental studies show promising results, this potential benefit remains under investigation
Still, month-to-month comparisons across men and women arent especially useful
Here is how Tirzepatide compares: In the SURMOUNT-5 head-to-head trial, 751 adults with obesity (but without type 2 diabetes) were randomised to receive either Tirzepatide or semaglutide at their maximum tolerated doses for 72 weeks